Browse News
Filter News
Found 3,130 articles
-
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
4/17/2024
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
-
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
4/10/2024
Inspira™ Technologies OXY B.H.N. Ltd. together with Ennocure MedTech Ltd. ("Ennocure"), announced results from their collaborative development of a proprietary bio-electronic treatment to prevent associated bloodstream infections in patients in intensive care units.
-
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
4/10/2024
Scinai Immunotherapeutics Ltd. announced that the company's Chief Science Officer, Dr. Tamar Ben-Yedidia, and the University Medical Center Göttingen's Director, Department of Dermatology, Venereology & Allergology, Prof. Michael Schön, will be presenting together at the upcoming 5th Dermatology Drug Development Summit Europe, which will take place in Berlin between April 16-18, 2024.
-
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
4/8/2024
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement (MSA) with the Company's CDMO business unit, Scinai Bioservices.
-
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
4/8/2024
Entera Bio Ltd. announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).
-
SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis
4/3/2024
SpliSense today announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 study for SPL84 in CF. SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
-
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
3/27/2024
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
3/26/2024
Entera Bio Ltd. announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months.
-
Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors
3/25/2024
Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, emerged from stealth with $20 million in Series A financing backed by Alta Partners to advance the clinical development of BTX-A51 in acute myeloid leukemia and a precision medicine approach to breast cancer.
-
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
3/25/2024
Alpha Tau Medical Ltd. today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11th , 2024.
-
XPlan.ai Confirms Premier Precision in Peer-Reviewed Clinical Study of its 2D-to-3D Knee Reconstruction Solution
3/21/2024
XPlan.ai, a spinoff of RSIP Vision that uses AI to democratize precision orthopedics, reaches a new milestone for its X-ray based 3D bone modeling system with the publication of a peer-reviewed clinical study confirming unprecedented, sub-mm accuracy in a variety of clinically relevant measurements.
-
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
3/20/2024
Entera Bio Ltd. announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: “OPK”, or “OPKO”) with Entera’s proprietary N-Tab™ technology.
-
Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors
3/20/2024
Rafa Laboratories, LTD., a leading manufacturer of Emergency Medical Solutions, and the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, aim to enhance the national preparedness for nerve agent emergencies by developing a new design for Rafa's pediatric atropine autoinjectors.
-
Scinai leadership to attend BIO-Europe Spring 2024
3/12/2024
Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit, announced that it will be participating in partnership meetings and exhibiting its CDMO services at the BIO-Europe Spring 2024 conference, taking place March 18 to 20 in Barcelona.
-
NeuroGenesis Reports Positive Results from Phase 2 Extension Study in Progressive Multiple Sclerosis Treated with NG-01 Cell Therapy
3/12/2024
NeuroGenesis Bio Inc. announced positive results from the interim analysis of the open-label extension period of a randomized, double-blind, placebo-controlled, Phase 2 clinical trial assessing the long-term effects of its lead asset, NG-01, on the two main serum biomarkers of MS activity and progression, on physical and cognitive assessments, and patient-reported outcomes in progressive MS.
-
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
3/8/2024
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
-
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
3/7/2024
Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2023 financial results and provided a corporate update.
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/7/2024
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
-
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
3/6/2024
BrainsWay Ltd., a world leader in advanced and non-invasive treatment for brain disorders, reported fourth quarter and full-year 2023 financial results and provided an operational update.
-
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
3/4/2024
Entera Bio Ltd. announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 1, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The NASDAQ Capital Market and the matter is now closed.